Comparison of plasma glucose and hba1c levels with glargine and detemir insulin in diabetes mellitus 2 patients at Ulin Regional Public Hospital, Banjarmasin

Background: Based on the International Diabetes Federation, the prevalence of diabetes in 2030 will be around 438 million people. In 2019, type 2 diabetes mellitus caused 4.2 million deaths in the world. Diabetes mellitus is a metabolic disorder that requires long-term therapy. Insulin is one of the therapies for type 2 diabetes mellitus. Parameters for monitoring the success of therapy were plasma glucose levels and Hba1c values. Objective: This study aimed to compare the values of plasma glucose and glycosylated hemoglobin (Hba1c) in insulin glargine and detemir patients with type 2 diabetes mellitus (DM) at Ulin Regional Public Hospital, Banjarmasin. Method: This study used a cross-sectional study design in March-May 2022 in 60 patients with type 2 DM at Ulin Regional Public Hospital, Banjarmasin. The data taken was in the form of fasting plasma glucose (FPG), 2-hour post-load plasma glucose (OGTT), and Hba1c values for 12 weeks. Statistical analysis was performed using the Mann-Whitney test with a confidence level of 95%. Results: The results showed that the average pre-post glargine FPG values were 212-139,6 mg/dL and the pre-post detemir FPG values were 224.6-159.8 mg/dL. Hba1c values in patients using glargine pre-post were 9.1% and 8.3%, and the average Hba1c values on insulin detemir pre-post were 9.28% and 8.29%. Conclusion: In therapy using insulin glargine compared to detemir, there was no significant difference between KGDP, KGD2PP, and Hba1C (p> 0.05).